44589-0 |
IgA.monoclonal |
PrThr |
CSF |
Pt |
Ord |
Immunofixation |
|
ACTIVE |
IgA.monoclonal [Presence] in Cerebral spinal fluid by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44589-0 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
M-IgA CSF Ql IFE |
|
|
|
N |
|
Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; IFE; Ifix; Immune globulin A; Immunofixation electrophoresis; Immunoglobulin A; M-IgA; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
4459-4 |
Vancomycin |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Vancomycin [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4459-4 |
|
|
|
|
Observation |
|
|
|
0 |
Vancomycin Dose |
|
|
|
Y |
|
c162; Dose med or substance; DRUG DOSES; Point in time; QNT; Quan; Quant; Quantitative; Random; VANC; Vancocin; Vancor |
2.73 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
44590-8 |
IgA.secretory |
PrThr |
Saliva |
Pt |
Ord |
|
|
ACTIVE |
IgA.secretory [Presence] in Saliva (oral fluid) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44590-8 |
|
|
|
|
Both |
|
|
|
0 |
SIgA Sal Ql |
|
|
|
N |
|
Chemistry; Immune globulin A; Immunoglobulin A; Oral fluid; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Sal; Salivary IgA; Screen; sIgA |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44591-6 |
IgD |
PrThr |
Urine |
Pt |
Ord |
Immunofixation |
|
ACTIVE |
IgD [Presence] in Urine by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44591-6 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
IgD Ur Ql IFE |
|
|
|
N |
|
Chemistry; Hematology; Heme; IFE; Ifix; Immune globulin D; Immunofixation electrophoresis; Immunoglobulin D; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44592-4 |
IgD |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
IgD [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44592-4 |
|
|
|
|
Both |
|
|
|
0 |
IgD Ser Ql |
|
|
|
N |
|
Chemistry; Immune globulin D; Immunoglobulin D; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44593-2 |
IgE |
PrThr |
Urine |
Pt |
Ord |
Immunofixation |
|
ACTIVE |
IgE [Presence] in Urine by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44593-2 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
IgE Ur Ql IFE |
|
|
|
N |
|
Chemistry; Hematology; Heme; IFE; Ifix; Immune globulin E; Immunofixation electrophoresis; Immunoglobulin E; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44594-0 |
IgE |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
IgE [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44594-0 |
|
|
|
|
Both |
|
|
|
0 |
IgE Ser Ql |
|
|
|
N |
|
Chemistry; Immune globulin E; Immunoglobulin E; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44595-7 |
IgG |
PrThr |
Urine |
24H |
Ord |
Immunofixation |
|
ACTIVE |
IgG [Presence] in 24 hour Urine by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44595-7 |
|
Immunofixation |
|
|
Both |
|
|
|
0 |
IgG 24h Ur Ql IFE |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; IFE; Ifix; Immune globulin G; Immunofixation electrophoresis; Immunoglobulin G; Ordinal; PR; QL; Qual; Qualitative; Screen; UA; UR; Urn |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44596-5 |
IgG Ag |
PrThr |
Skin |
Pt |
Ord |
IF |
|
ACTIVE |
IgG Ag [Presence] in Skin by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
44596-5 |
|
IF |
|
|
Both |
|
|
|
0 |
IgG Ag Skin Ql IF |
|
|
|
N |
|
ACIF; Anticomplement Immunofluorescence; Antigen; Antigens; Dermatologic; DFA; Epidermis; FA; Fluorescent antibody; Fluoresent; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Integument; Ordinal; PATHOLOGY; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Skn; Time Resolved Fluorescence; TRF |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44597-3 |
IgG.monoclonal |
PrThr |
Ser |
Pt |
Ord |
Immunofixation |
|
ACTIVE |
IgG.monoclonal [Presence] in Serum by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44597-3 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
M-IgG Ser Ql IFE |
|
|
|
N |
|
Chemistry; IFE; Ifix; Immune globulin G; Immunofixation electrophoresis; Immunoglobulin G; M-IgG; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44598-1 |
IgG.monoclonal |
PrThr |
Urine |
Pt |
Ord |
Immunofixation |
|
ACTIVE |
IgG.monoclonal [Presence] in Urine by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44598-1 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
M-IgG Ur Ql IFE |
|
|
|
N |
|
Chemistry; Hematology; Heme; IFE; Ifix; Immune globulin G; Immunofixation electrophoresis; Immunoglobulin G; M-IgG; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44599-9 |
IgG.monoclonal |
PrThr |
CSF |
Pt |
Ord |
Immunofixation |
|
ACTIVE |
IgG.monoclonal [Presence] in Cerebral spinal fluid by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44599-9 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
M-IgG CSF Ql IFE |
|
|
|
N |
|
Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; IFE; Ifix; Immune globulin G; Immunofixation electrophoresis; Immunoglobulin G; M-IgG; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
446-5 |
Roxithromycin |
Titr |
Isolate+Ser |
Pt |
SemiQn |
SBT |
|
ACTIVE |
Roxithromycin [Susceptibility] by Serum bactericidal titer |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
ABXBACT |
|
446-5 |
|
SBT |
|
|
Observation |
|
|
|
0 |
Roxithromycin Titr SBT |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; Assoral; c161; Cirumycin; Claramid; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Islt; Isol; Macrosil; Overal; Point in time; Random; Rossitrol; Rotesan; Rotramin; Rulid; Sequence based typing; Serum; SERUM BACTERICIDAL TITER; Serum killing test; SmQn; SR; Surlid; Titer; Titered; Titre; Ttr |
2.75 |
1 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
4460-2 |
Verapamil |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Verapamil [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4460-2 |
|
|
|
|
Observation |
|
|
|
0 |
Verapamil Dose |
|
|
|
Y |
|
APO-TRIMIP; Calan; Dose med or substance; DRUG DOSES; Isoptin; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
44600-5 |
IgM |
PrThr |
Urine |
24H |
Ord |
Immunofixation |
|
ACTIVE |
IgM [Presence] in 24 hour Urine by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44600-5 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
IgM 24h Ur Ql IFE |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; IFE; Ifix; Immune globulin M; Immunofixation electrophoresis; Immunoglobulin M; Ordinal; PR; QL; Qual; Qualitative; Screen; UA; UR; Urn |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44601-3 |
IgM.monoclonal |
PrThr |
Ser |
Pt |
Ord |
Immunofixation |
|
ACTIVE |
IgM.monoclonal [Presence] in Serum by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44601-3 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
M-IgM Ser Ql IFE |
|
|
|
N |
|
Chemistry; IFE; Ifix; Immune globulin M; Immunofixation electrophoresis; Immunoglobulin M; M-IgM; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44602-1 |
IgM.monoclonal |
PrThr |
Urine |
Pt |
Ord |
Immunofixation |
|
ACTIVE |
IgM.monoclonal [Presence] in Urine by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44602-1 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
M-IgM Ur Ql IFE |
|
|
|
N |
|
Chemistry; Hematology; Heme; IFE; Ifix; Immune globulin M; Immunofixation electrophoresis; Immunoglobulin M; M-IgM; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44603-9 |
IgM.monoclonal |
PrThr |
CSF |
Pt |
Ord |
Immunofixation |
|
ACTIVE |
IgM.monoclonal [Presence] in Cerebral spinal fluid by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44603-9 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
M-IgM CSF Ql IFE |
|
|
|
N |
|
Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; IFE; Ifix; Immune globulin M; Immunofixation electrophoresis; Immunoglobulin M; M-IgM; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44604-7 |
Immunoglobulin light chains.kappa.free |
PrThr |
Urine |
Pt |
Ord |
Immunofixation |
|
ACTIVE |
Kappa light chains.free [Presence] in Urine by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44604-7 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
Kappa LC Free Ur Ql IFE |
|
|
|
N |
|
Bence Jones protein; BJ Protein; BJP; Chain; Chemistry; FR; Hematology; Heme; IFE; Ifix; Immune globulin; Immuno; Immunofixation electrophoresis; Immunoglob; Immunoglobin; Imunoglbon; Imunoglobn; Kappa LC; Kappa LC Free; Non-protein bound; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.63 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. Changed the LCN from 'Immunoglobulin light chains.kappa.free' to ' Kappa light chains.free' for readability. |
0 |
44605-4 |
Immunoglobulin light chains.kappa |
PrThr |
CSF |
Pt |
Ord |
Immunofixation |
|
ACTIVE |
Kappa light chains [Presence] in Cerebral spinal fluid by Immunofixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44605-4 |
|
Immunofixation |
|
|
Observation |
|
|
|
0 |
Kappa LC CSF Ql IFE |
|
|
|
N |
|
Bence Jones protein; BJ Protein; BJP; Cerebral spinal fluid; Cerebrospinal Fl; Chain; Chemistry; IFE; Ifix; Immune globulin; Immuno; Immunofixation electrophoresis; Immunoglob; Immunoglobin; Imunoglbon; Imunoglobn; Kappa LC; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.63 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. Changed the LCN from 'Immunoglobulin light chains.kappa' to ' Kappa light chains' for readability |
0 |
44606-2 |
ALOX3+ALOX12B gene targeted mutation analysis |
Prid |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
ALOX3+ALOX12B gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
44606-2 |
|
Molgen |
|
|
Both |
|
|
|
0 |
ALOX3+ALOX12B gene Mut Anl Bld/T |
|
|
|
N |
|
12R-LOX; ALOX genes; Arachidonate 12-lipoxygenase, 12R type; Arachidonate lipoxygenase 3 gene; Blood; Epidermis-type lipoxygenase 3 gene; Genetics; Heredity; Heritable; Identity or presence; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; Nominal; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.63 |
2.17 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section. |
0 |
44607-0 |
HIV 1 |
Imp |
Ser/Plas |
Pt |
Nom |
IA |
|
ACTIVE |
HIV 1 [Interpretation] in Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44607-0 |
|
IA |
|
|
Observation |
|
|
|
0 |
HIV1 SerPl IA-Imp |
|
|
|
N |
|
AIDS; EIA; ELFA; ELISA; Enzyme immunoassay; HIV type 1; HIV type I; HIV1; Human immunodeficiency virus; i; IAA; ID; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; MEIA; Microbiology; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
Updated system from Ser to Ser/Plas; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
44608-8 |
KCNQ1 gene mutations tested for |
Prid |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
KCNQ1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal |
|
MIN |
DefinitionDescription |
|
|
|
SOUTHERN BLOT ANALYSIS IS UTILIZED TO DETECT Abnormal METHYLATION IN THE IMPRINTING CENTER DMR2, WHICH IS LOCATED WITHIN THE BWS CRITICAL REGION ON CHROMOSOME 11P15. THE DNA PROBE LIT1 IS USED FOR THIS ANALYSIS. A STATE OF HYPOMETHYLATION OR Normal METHYLATION IS DISTINGISHED BASED ON PRE-DETERMINED METHYLATION INDICES (REFERENCE RANGE: 0.40-0.58). |
|
|
|
|
|
MOLPATH.MUT |
|
44608-8 |
|
Molgen |
|
|
Both |
|
|
|
0 |
KCNQ1 gene Mut Tested Bld/T |
|
|
|
N |
|
ATFB1; ATFB3; Blood; Gene mut tested; Genetics; Heredity; Heritable; Identity or presence; Inherited; JLNS1; KCNA8; KCNA9; KCNQ10T1; Kv1.9; Kv7.1; KVLQT1; Long (electrocardiographic) QT syndrome, Ward-Romano syndrome 1; LQT; LQT1; LQTS; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Tested; Mutation; Muts; Nominal; PCR; Point in time; potassium channel, voltage gated KQT-like subfamily Q, member 1; Potassium voltage-gated channel, KQT-like subfamily, member 1; Random; RWS; SQT2; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue; WRS |
2.17 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
44609-6 |
Heart rate |
NRat |
Capillary bed |
Episode^max |
Qn |
Oximetry |
|
DEPRECATED |
Deprecated Heart rate Episode maximum by Oximetry |
|
DEL |
DefinitionDescription |
|
|
beats/min |
|
|
|
|
|
|
HRTRATE.MOLEC |
|
44609-6 |
|
Oximetry |
|
|
Observation |
|
|
|
0 |
Deprecated Heart rate Episode Max Oximet |
|
|
|
N |
|
Count/time; Heart beat; HEART RATE.MOLEC; Maximum; nRate; Number rate; Number Rate = Count/Time; Pulse; QNT; Quan; Quant; Quantitative |
2.54 |
2.17 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
4461-0 |
Warfarin |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Warfarin [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
mg |
|
|
|
|
|
|
DRUGDOSE |
|
4461-0 |
|
|
|
|
Observation |
|
|
|
0 |
Warfarin Dose |
|
|
|
Y |
|
4-Hydroxycoumarin; Coumadin; Coumarin; Coumarins; Dose med or substance; DRUG DOSES; Panwarfin; Point in time; QNT; Quan; Quant; Quantitative; Random; Sofarin |
2.73 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |